BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34933802)

  • 1. Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
    Stankunaite R; George SL; Gallagher L; Jamal S; Shaikh R; Yuan L; Hughes D; Proszek PZ; Carter P; Pietka G; Heide T; James C; Tari H; Lynn C; Jain N; Portela LR; Rogers T; Vaidya SJ; Chisholm JC; Carceller F; Szychot E; Mandeville H; Angelini P; Jesudason AB; Jackson M; Marshall LV; Gatz SA; Anderson J; Sottoriva A; Chesler L; Hubank M
    Eur J Cancer; 2022 Feb; 162():209-220. PubMed ID: 34933802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
    George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
    Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
    Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
    BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
    Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
    Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
    Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
    Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving detection of circulating tumor DNA using next generation sequencing.
    Tébar-Martínez R; Martín-Arana J; Gimeno-Valiente F; Tarazona N; Rentero-Garrido P; Cervantes A
    Cancer Treat Rev; 2023 Sep; 119():102595. PubMed ID: 37390697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 8. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
    Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
    Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
    Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B
    Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.
    Cario CL; Chen E; Leong L; Emami NC; Lopez K; Tenggara I; Simko JP; Friedlander TW; Li PS; Paris PL; Carroll PR; Witte JS
    BMC Cancer; 2020 Aug; 20(1):820. PubMed ID: 32859160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
    Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
    Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
    Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
    J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
    Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
    Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
    Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
    Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA.
    Huebner A; Black JRM; Sarno F; Pazo R; Juez I; Medina L; Garcia-Carbonero R; Guillén C; Feliú J; Alonso C; Arenillas C; Moreno-Cárdenas AB; Verdaguer H; Macarulla T; Hidalgo M; McGranahan N; Toledo RA
    Genome Med; 2023 Apr; 15(1):27. PubMed ID: 37081523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
    Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
    Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.
    Gašperšič J; Videtič Paska A
    Biochem Med (Zagreb); 2020 Oct; 30(3):030504. PubMed ID: 32774122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.